secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001104659-22-087227
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q2 net product rev $12.1M (+9% YoY); net loss $18.8M; FY guidance reaffirmed
--------------------------------------------------------------------------------

- DEXTENZA net product revenue $12.1M in Q2 2022, up 9% YoY from $11.1M; total net revenue $12.3M.
- Net loss $18.8M ($0.24 basic / $0.25 diluted EPS) vs $8.5M loss in Q2 2021.
- Reiterates FY2022 DEXTENZA net product revenue guidance of $55-60M (26%-38% growth).
- Cash and equivalents $134.5M at June 30, 2022; expects to fund operations through 2023.
- Interim OTX-TKI (wet AMD) Phase 1 data to be presented at AAO in September 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922087227/0001104659-22-087227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922087227/tm2222774d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-087227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer